Conference Proceedings
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel
Stephen J Schuster, Michael R Bishop, Constantine Tam, Peter Borchmann, Ulrich Jaeger, Edmund K Waller, Harald Holte, Joseph P McGuirk, Samantha Jaglowski, Kensei Tobinai, Charalambos Andreadis, Isabelle Fleury, Stephan Mielke, Takanori Teshima, Jason R Westin, Veronika Bachanova, Stephen Ronan Foley, P Joy Ho, John M Magenau, Nina D Wagner-Johnston Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Abstract BACKGROUND JULIET (NCT02445248) is a single-arm, open-label, multicenter, global, pivotal phase 2 trial of tisagenlecleucel, a chimeric antigen receptor (CAR)-T cell therapy targeting CD19, that has shown a high rate of durable complete responses (CR) and a manageable safety profile in adult patients with clinically active relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The primary objective was met at the interim analysis, with an overall response rate (ORR) of 59% (CR, 43%; partial response [PR], 16%). Here, we present an updated analysis of the JULIET trial, with a median of 19 months of follow-up, an additional 5 mon..
View full abstract